BiVac Polio (bivalent oral polio vaccine, live attenuated types 1, 3) 0.2 ml/dose, 10 pcs.

The vaccine is a preparation of attenuated Sabin strains of poliomyelitis virus types 1, 3 grown on primary culture of African green monkey kidney cells or on primary culture of African green monkey kidney cells with one pass on transplanted culture of Vero line cells and contains two types of virus (bivalent vaccine) as a solution with 0.5% lactalbumin hydrolysate in Earl solution. The vaccine creates persistent immunity to polio virus types 1,3 in (90-95)% of those vaccinated.

Indications

Active prevention of polio.

Active ingredient

Composition

1 dose (0.2 ml – 4 drops) contains:

Active ingredient:Polio virus, attenuated Sabin type 1 strains not less than 106.0 TCD50, type 3 not less than 105.5 TCD50 Infectious units (IU) of the virus, expressed in tissue cytopathogenic doses (TCD50);

Auxiliary substances: Magnesium chloride 0.018 g; kanamycin 30 µg.

How to take, the dosage

Attention! The vaccine is for oral administration only.

The vaccine is administered in 4 drops per dose. The vaccine dose should be put into the mouth with the dropper or dropper supplied with the bottle 1 hour before the meal. Drinking the vaccine with water or any other liquid, or eating or drinking for one hour after vaccination is not allowed.

In accordance with the current version of the National Preventive Immunization Calendar, the first and second polio vaccinations are given to children with inactivated polio vaccine (IPV), in accordance with the instructions for use of IPV.

The third vaccination and subsequent revaccinations against polio are given to children with live oral polio vaccine (LIP).

The first three vaccinations make up the vaccination course.

Interaction

Polio vaccinations are allowed to be administered on the same day as vaccination with DPT-vaccine (ADS- or ADS-M anatoxin), simultaneous administration of polio vaccine with other preparations of the National Preventive Vaccination Calendar is allowed.

Special Instructions

Parents should be notified in advance about the day of their children’s upcoming preventive vaccinations.

The scheduled vaccination of children with exacerbations of chronic diseases is postponed until a full recovery.

Unused vaccine from an opened bottle can be stored for up to 2 days at 2 to 8°C in a bottle, tightly closed with a dropper or rubber stopper. If necessary, the vaccine may be taken with a sterile syringe by puncturing the rubber stopper while following aseptic rules. In this case, the vaccine remaining in the bottle and not changing its physical properties may be used until the end of the shelf life.

The drug is not suitable for use in a bottle with compromised integrity, markings, as well as if its physical properties have changed (color, transparency, etc.), the expiration date has expired, transportation and storage conditions have been violated.

Impact on the ability to drive vehicles and operate machinery

The vaccine does not affect the ability to drive vehicles.

Contraindications

Neurological disorders accompanying previous vaccination with oral polio vaccine; immunodeficiency state (primary), malignant neoplasms, immunosuppression (vaccination is carried out not earlier than 3 months after the end of therapy); Hypersensitivity to any component of the vaccine; strong reaction (temperature above 40 ° C) or complications of previous administration of the drug; pregnancy; acute infectious or non-infectious diseases, exacerbation of chronic diseases – vaccination is carried out in 2-4 weeks after recovery or remission. In cases of non-serious acute respiratory infections and acute intestinal diseases the vaccination shall be carried out after the normalization of temperature.

Side effects

Reactions (except immediate allergic reactions in the first few hours after vaccination) usually cannot occur before the 4th day and more than 30 days after vaccination.

Rarely non-specific symptoms: fever, vomiting, headache, not necessarily related to taking the oral polio vaccine.

Very rare- Allergic reactions in the form of urticaria or Quincke’s edema may occur in individual vaccinees.

Frequent cases – both in vaccinated persons and persons in contact with vaccinated persons – occurrence of vaccine-associated paralytic poliomyelitis (VAPP). To prevent VAPP, the first two vaccinations against poliomyelitis are carried out with IPV vaccine.

Overdose

Overdose does not lead to undesirable consequences.